Pneumocystis jiroveci pneumonia following rituximab treatment in Wegener's granulomatosis

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Arthritis care & research

• Publication date

  2010-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/acr.20279PMID 20583109
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients.

  2014cited by this paper
• Depletion of functionally active CD20+ T cells by rituximab treatment.

  2009cited by this paper
• EULAR recommendations for the management of primary small and medium vessel vasculitis

  2008cited by this paper
• Analysis of Wegener’s Granulomatosis Responses to Rituximab: Current Evidence and Therapeutic Prospects

  2008cited by this paper
• Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis.

  2008cited by this paper
• Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials.

  2007cited by this paper
• Clinical features and outcome of pediatric Wegener's granulomatosis.

  2007cited by this paper
• B Cells Are Required for Generation of Protective Effector and Memory CD4 Cells in Response to Pneumocystis Lung Infection

  2006cited by this paper
• X-linked agammaglobulinaemia and Pneumocystis carinii pneumonia—an unusual coincidence?

  2003cited by this paper
• Clearance of Pneumocystis carinii in Mice Is Dependent on B Cells But Not on P. carinii-Specific Antibody 1

  2003cited by this paper
• Rituximab for refractory childhood autoimmune hemolytic anemia.

  2002cited by this paper
• Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality.

  1999cited by this paper
• Pneumocystis carinii infection in transgenic B cell-deficient mice.

  1996cited by this paper
• Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis.

  1995cited by this paper
• Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases.

  1994cited by this paper

• Pneumocystis jirovecii infection in autologous hematopoietic stem cell transplantation.

  2026cites this paper
• Targeted next-generation sequencing of bronchoalveolar lavage fluid for pathogen detection in connective tissue disease-related pulmonary infections

  2025cites this paper
• Case report: A HIV-negative hemodialysis patient positive for pANCA with severe pneumocystis pneumonia: A case report and review of literature

  2023cites this paper
• Case Report: Successful treatment of severe pneumocystis carinii pneumonia in a case series of primary nephrotic syndrome after receiving anti-CD20 monoclonal antibody therapy

  2023cites this paper
• The Efficacy and Safety of Rituximab in ANCA-Associated Vasculitis: A Systematic Review

  2022cites this paper
• Consensus Treatment Plans for Severe Pediatric Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

  2021cites this paper
• Targeted therapies for autoimmune/idiopathic nonmalignant diseases: risk and management of opportunistic infections

  2020cites this paper
• TRAb measurement: evaluation of the cut-off value RFA for hyperactive thyroid adenoma A Dutch consensus on AAV diagnosis and treatment Type I cryoglobulinaemic vasculitis

  2020cites this paper
• Recent advances and future directions in the management of the immunocompromised host.

  2020cites this paper
• Rituximab identified as an independent risk factor for severe PJP: A case-control study

  2020cites this paper
• Pulmonary Involvement in the Systemic Inflammatory Diseases of Childhood

  2019cites this paper
• A Dutch consensus statement on the diagnosis and treatment of ANCA-associated vasculitis.

  2019cites this paper
• Relapse of nephrotic syndrome during post-rituximab peripheral blood B-lymphocyte depletion

  2018cites this paper
• Pneumocystis jirovecii pneumonia in HIV-uninfected, rituximab treated non-Hodgkin lymphoma patients

  2018cites this paper
• Invasive fungal infections in paediatric patients treated with macromolecular immunomodulators other than tumour necrosis alpha inhibitors

  2017cites this paper
• Pneumocystis Pneumonia and the Rheumatologist: Which Patients Are At Risk and How Can PCP Be Prevented?

  2017cites this paper
• Rituximab for immunologic renal disease: What the nephrologist needs to know.

  2017cites this paper
• Antibody-Independent Function of Human B Cells Contributes to Antifungal T Cell Responses

  2017cites this paper
• Detection of Pneumocystis jirovecii in oral wash from immunosuppressed patients as a diagnostic tool

  2017cites this paper
• Pneumocystis jirovecii and Pneumocystosis

  2017cites this paper
• [Pneumocystosis during HIV infection].

  2016cites this paper
• Rituximab as maintenance therapy for ANCA associated vasculitis: how, when and why?

  2016cites this paper
• CanVasc Recommendations for the Management of Antineutrophil Cytoplasm Antibody-associated Vasculitides

  2016cites this paper
• Fungal infection involvement in primary biliary cirrhosis: A review of 2 cases

  2016cites this paper
• La pneumocystose au cours de l’infection à VIH

  2016cites this paper
• Rituximab as maintenance therapy for ANCA associated vasculitis: how, when and why?

  2016cites this paper
• Granulomatous Reaction to Pneumocystis jirovecii Diagnosed in a Bronchoalveolar Lavage: A Case Report

  2015cites this paper
• Prophylaxis and Treatment of Pneumocystis jiroveci Pneumonia in Lymphoma Patients Subjected to Rituximab-Contained Therapy: A Systemic Review and Meta-Analysis

  2015cites this paper
• Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitis

  2014cites this paper
• Treatment of ANCA-associated vasculitis: new therapies and a look at old entities.

  2014cites this paper
• C URRENT OPINION Is B-cell depletion first choice in antineutrophil cytoplasmic antibody-associated vasculitis?

  2014cites this paper
• Pneumocystis jirovecii pneumonia in two patients with systemic lupus erythematosus after rituximab therapy

  2014cites this paper
• Is B-cell depletion first choice in antineutrophil cytoplasmic antibody-associated vasculitis?

  2014cites this paper
• Late‐onset Pneumocystis jirovecii pneumonia in solid organ transplant recipients

  2014cites this paper
• Pneumocystis jiroveci pneumonia in immunocompromised patients: delayed diagnosis and poor outcomes in non-HIV-infected individuals.

  2014cites this paper
• A dose-escalation regimen of trimethoprim–sulfamethoxazole is tolerable for prophylaxis against Pneumocystis jiroveci pneumonia in rheumatic diseases

  2013cites this paper
• Pneumocystis jirovecii Pneumonia in Systemic Lupus Erythematosus From Southern Taiwan

  2013cites this paper
• Recent‐onset systemic lupus erythematosus complicated by acute respiratory failure

  2013cites this paper
• Leveraging administrative data to monitor rituximab use in 2875 patients at 42 freestanding children's hospitals across the United States.

  2013cites this paper
• Pneumocystis pneumonia in patients treated with rituximab.

  2013cites this paper
• Pneumocystis jiroveci pneumonia in patients with non-Hodgkin's lymphoma after Rituximab-containing regimen: two cases of report and literature review.

  2013cites this paper
• Diagnosis and Management of Infectious Complications of Childhood Rheumatic Diseases

  2013cites this paper
• 108 – Pediatric Systemic Lupus Erythematosus, Dermatomyositis, Scleroderma, and Vasculitis

  2013cites this paper
• Atypical Pneumocystis jiroveci pneumonia with multiple nodular granulomas after rituximab for refractory nephrotic syndrome

  2012influential citation
• Colonization by Pneumocystis jirovecii and Its Role in Disease

  2012cites this paper
• Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center.

  2012cites this paper
• Complications of long-term therapy for ANCA-associated systemic vasculitis

  2012cites this paper
• Granulomatosis with Polyangiitis in Childhood

  2012cites this paper
• [Pneumocystis jirovecii pneumonia in HIV-infected patients].

  2012cites this paper
• [Immunologic changes in diffuse large B-cell lymphomas after rituximab-CHOP treatment: own data and review of the literature].

  2012cites this paper
• 57 – Pulmonary Involvement in the Systemic Inflammatory Diseases of Childhood

  2012cites this paper
• Pneumocystis jiroveci pneumonia in patients with systemic lupus erythematosus after rituximab therapy

  2012cites this paper
• Pediatric Systemic Lupus Erythematosus , Dermatomyositis , Scleroderma , and Vasculitis

  2012cites this paper
• Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis.

  2012cites this paper
• Immunosuppressive and Cytotoxic Therapy: Pharmacology, Toxicities, and Monitoring

  2011cites this paper
• A Systematic Review and Meta-Analysis of Rituximab in Antibody-mediated Renal Allograft Rejection

  2011cites this paper
• Phenotypic Evaluation of B-Cell Subsets After Rituximab for Treatment of Acute Renal Allograft Rejection in Pediatric Recipients

  2011cites this paper
• Pneumocystis jirovecii pneumonia in non-HIV-infected patients: new risks and diagnostic tools

  2011cites this paper